Trifluridine, Tipiracil
Overview
Trifluridine and tipiracil is an oral fixed-dose anticancer combination used in the treatment of advanced gastrointestinal malignancies. Trifluridine is a thymidine-based nucleoside analog that becomes incorporated into DNA, interfering with DNA synthesis and inhibiting tumor cell proliferation. Tipiracil is a thymidine phosphorylase inhibitor that prevents rapid degradation of trifluridine, thereby increasing systemic exposure and enhancing antitumor activity. Together, the combination provides sustained cytotoxic effects against rapidly dividing cancer cells. The therapy is administered orally and is commonly used in patients with metastatic colorectal cancer or metastatic gastric and gastroesophageal junction adenocarcinoma who have previously received multiple lines of systemic treatment. The drug offers an additional therapeutic option for heavily pretreated patients with limited remaining treatment alternatives.
Background and Date of Approval
The trifluridine and tipiracil combination was developed to improve delivery and efficacy of trifluridine through inhibition of its rapid metabolism. The United States Food and Drug Administration approved the combination on September 22, 2015 for patients with metastatic colorectal cancer previously treated with standard chemotherapies, anti-VEGF therapy, and anti-EGFR therapy where appropriate. Subsequently, on February 22, 2019, the United States Food and Drug Administration approved trifluridine and tipiracil for metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior chemotherapy regimens. More recently, on August 2, 2023, the United States Food and Drug Administration approved trifluridine and tipiracil in combination with bevacizumab for metastatic colorectal cancer following progression after prior chemotherapy. These approvals were supported by major clinical studies including the RECOURSE, TAGS, and SUNLIGHT Phase III trials demonstrating improvements in overall survival and disease control.
Uses
Trifluridine and tipiracil is indicated for the treatment of metastatic colorectal cancer in patients previously treated with standard chemotherapy regimens and targeted therapies where applicable. It is also indicated for metastatic gastric or gastroesophageal junction adenocarcinoma in patients who have received prior treatment. In selected patients, the combination may be used with bevacizumab to improve clinical outcomes in metastatic colorectal cancer.
Administration
Trifluridine and tipiracil is administered orally twice daily on specific days within a 28-day treatment cycle. Dosing is based on body surface area and should be taken within one hour after completion of meals. Treatment continues until disease progression or unacceptable toxicity occurs. Dose interruptions and reductions may be necessary depending on hematologic or gastrointestinal adverse reactions. Regular laboratory monitoring is essential during therapy.
Side Effects
Common side effects include fatigue, nausea, vomiting, diarrhea, abdominal pain, decreased appetite, anemia, neutropenia, thrombocytopenia, and fever. Weakness and gastrointestinal discomfort are also frequently reported. These effects are generally manageable with supportive care and dose modifications.
Warnings
Serious adverse reactions include severe myelosuppression, particularly neutropenia, which may increase the risk of serious infections and febrile neutropenia. Severe anemia and thrombocytopenia may also occur. Gastrointestinal toxicity including severe diarrhea and dehydration requires careful management. Embryo-fetal toxicity is a significant concern due to the cytotoxic mechanism of action. Treatment interruption or discontinuation may be necessary in severe toxicity cases.
Precautions
Patients should undergo baseline complete blood count assessment and regular hematologic monitoring during treatment. Caution is required in patients with hepatic or renal impairment. Concomitant use with other myelosuppressive therapies may increase hematologic toxicity risk. Although major cytochrome-mediated drug interactions are limited, clinical vigilance is required in patients receiving multiple anticancer agents or supportive medications.
Expert Tips
Trifluridine and tipiracil is best suited for patients with advanced gastrointestinal cancers who have exhausted standard first-line and second-line therapies. Strict monitoring of blood counts is essential, especially during early treatment cycles. Clinicians should counsel patients regarding infection risk, fever reporting, and adherence to meal-related administration instructions. Dose modifications should be implemented promptly when significant hematologic toxicity develops. Coordination with oncology pharmacists and supportive care teams can improve treatment tolerability and adherence.